Trial Profile
A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Tegaserod (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Aug 2016 New trial record